Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 121 participants.
Also called NCT02117453
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 121 participants
- Registry
-
NCT02117453 -
2013-002531-15
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT02117453. Randomized; quadruple masking; primary purpose prevention. Start 2014-10-27 (actual); primary completion 2019-11-07 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Multicenter, Prospective, Randomized, Controlled, Double-blind Trial on the Impact of Rosuvastatin on Subclinical Markers of Atherosclerosis in Patients With Primary Necrotizing Vasculitides
- Acronym
- STATVAS
- Condition
- ANCA-associated Primary Necrotizing Vasculitides
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Collaborator
- URC-CIC Paris Descartes Necker Cochin
Record details
- Record id
cardio:ct-nct02117453- Content hash
a5b9675fa8ac9569fc6b08a4fb27edd9a80b5069ebdb173ed7be8b5664230c6c